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IMMUNOMODULATING effects of a neoglycoconjugate cre-
ated  on  the  basis  of  a 1-acid  glycoprotein  (AGP)
carbohydrate chains and  synthetic protein-free car-
rier have been investigated. It was demonstrated that
this  pseudo-AGP  suppressed  PHA-  or  anti-CD3  anti-
body-induced  lymphocyte  proliferation  in  a  dose-
dependent  manner.  Pseudo-AGP  revealed  a  similar
antiproliferative  effect  as  the  natural  AGP  samples.
Stimulation  of  the  LPS-induced  proinflammatory
cytokine  production  by  mononuclear  cells  treated
with  both  natural  and  pseudo-AGP  has  been  also
demonstrated.  These  data  show  that  carbohydrate
chains  of  AGP  play  a  crucial  role  in  the  studied
biological effect realization.
Key words: a 1-acid glycoprotein, Neoglycoconjugate, Anti-
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Introduction
The inflammatory reaction leads to alterations in the
concentration  of  certain  plasma  protein commonly
referred  to  as  acute-phase  proteins.  One  of  these
proteins  is  a 1-acid  glycoprotein  (AGP)  which  has
multiple immunomodulating effects. Thus, AGP exerts
an inhibitory effect on the proliferation of lympho-
cytes stimulated with anti-CD3 antibodies1, PHA2 and
in  mixed  lymphocyte  culture.3 AGP  significantly
enhances the production of inflammatory cytokines
interleukin (IL)-1b , IL-6, and tumour necrosis factor-a
(TNF-a ).4,5 In the same time monocytes/macrophages
treated  with  AGP  release  interleukin-1  inhibitory
factor.6,7 These data confirm the role of AGP as an
element  of  cytokine  network.  Immunomodulating
properties of AGP depend on microheterogeneity of
carbohydrate chains. In normal serum, three different
glycoforms of AGP are present: conconavalin A (Con
A)  unreactive AGP  (AGP-A), Con A weakly  reactive
AGP (AGP-B), and Con A strongly reactive AGP (AGP-
C).  These  molecular  forms  contain  carbohydrate
chains with different number of antennae and neu-
raminic acid residues. Tri- and tetraantennary carbohy-
drate chains only are present on the AGP-A.8–10 AGP-A
is more effective in modulation of lymphocyte pro-
liferation1,6 and inhibition of interleukin-2 production
by  peripheral  blood  lymphocytes.2 Nevertheless,
there is no distinct answer to the question of what is
the role of carbohydrate moiety and of the peptide
core  of AGP  molecule. Thus,  several  investigations
demonstrate  the  participation  of  AGP  glycans  in
suppression of the mitogen-induced lymphocyte pro-
liferation.1,11 On the other hand, there is an opinion
that the glycan moiety of AGP is not involved in the
potentiation of cytokine secretion triggered by LPS.4
In  this  work  the  discrimination  between  the  men-
tioned possibilities has been carried out by means of
quantitative  translocation  of  carbohydrate  chains
from the protein onto an other polymer carrier.12,13
Material and Methods
Isolation of human AGP
AGP patterns were isolated from peripheral human
blood.  Blood serum  was  obtained  from  20  normal
individuals. AGP was isolated and purified by using
the ammonium sulphate precipitation and chromatog-
raphy on DEAE-cellulose and on Cibacron blue F3GA-
Sepharose  4B  (Pharmacia,  Sweden).  AGP-positive
fractions  were  desalted by dialysis and  lyophilized.
Preparations  of AGP  were  electrophoretically  pure
and  tested  for  the  presence  of  endotoxin  in  the
Limulus amoebocyte lysate test (Atlas Bioscan, UK).
Endotoxin content was below 500pg/mg.
Pseudo-AGP preparation
Pseudo-AGP  was  obtained  as  described  earlier.12
Briefly, 9.3mg of poly-4-nitrophenilakrilate, 3.2mg of
aminated AGP oligosaccharides and 100m l diisopro-
pilethylene  in  1ml  of  dimethylphormamide  were
mixed  and  kept  at  37°C  for  48h. Then  200m l  of
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incubated  for  16h  at  5°C.  Pseudo-AGP  has  been
purified by chromatography on Sepahadex LH-20 and
lyophilized  (yield  was  about  95%).  Carbohydrate
content  in  pseudo-AGP  (including  Neu5Ac)  corre-
sponds to parent AGP , as well as ratio of bi-, tri- and
tetraantennary N-chains.
Cell cultures
Mononuclear  cells  were  isolated  from  heparinized
peripheral  blood  of  healthy  volunteers  by  Ficoll-
Verographin gradient centrifugation. The cells were
washed  twice  and  resuspended  in  RPMI-1640
medium  (ICN,  UK)  supplemented  with  10%  heat
inactivated donor horse serum, 2 3 10–3 M HEPES,
2mM L-glutamine, 2.8 3 10–6 M 2-mercaptoethanol,
and 20m g/ml gentamycin. Cells (106 cells/ml) were
cultivated  for  16–18h  at  37°C  with  3m g/ml  of
Neisseria meningitidis lipopolysaccharide (LPS) and
AGP at five different concentrations within the dose
range  31.2–500mg/ml  in  a  humidified  atmosphere
containing 5% CO2 in the wells (1.5ml per well) of
24-well  plates  (Nunc,  Denmark).  The  cells  in  the
control  wells  were  incubated  with  LPS  only.  The
supernatants were collected and stored at –20°C until
cytokine activity examination.
Inhibition of PHA- or anti-CD3
antibody-induced lymphocyte proliferation by
AGP
Peripheral blood mononuclear cells (see above) were
cultivated  in  flat-bottomed  96-well  plates  (Nunc,
Denmark), and contained 5 3 104 cells in each well.
The  final concentration  of  PHA (Calbiochem,  USA)
was 5m g/ml. In some experiments lymphocytes were
stimulated with polyclonal anti-CD3 antibodies which
were  a  generous  gift  from  Dr  M.  Bliacher  (Gab-
richevsky Institute of Epidemiology and Microbiology,
Moscow). Inhibition of lymphocyte proliferation by
AGP  was  evaluated  at  six  different  concentrations
within the dose range 31.2–1000m g/ml. The control
wells  incubated  without  AGP  contained  a  culture
medium with mitogen or a culture medium only. The
cells were incubated for 72h at 37°C in a humidified
atmosphere (95% air; 5% CO2). Four hours before the
end of cultivation, each well was pulsed with 40kBq
of  [3H]-thymidine  (Isotope,  Russia). The  cells  were
harvested  with  a  cell  harvester  and  counted  on  a
liquid scintillation counter. Four wells of each concen-
tration  were  assayed  and  the  counts  per  minute
(counts/min)  were  averaged.  Percentage  inhibition
was calculated by dividing the counts/min in each
inhibited sample  by  the  counts/min  in the  sample
containing PHA subtracting only the background level
(counts/min in the wells with culture medium only)
from these values. The intensity of suppression was
estimated by probit-analysis and expressed as ED50: a
dose of immunosuppressive agent at which lympho-
cyte proliferation was 50% of its maximum.
TNF activity assay
TNF activity was determined by the method of Ruff
and Gifford14 with some modifications. Briefly, L929
cells were seeded at a density of 3 3 104 cells per well
in 96-well plates in 100m l of medium 199 to which
10% heat-inactivated calf bovine serum and gentamy-
cin had been added. Plates were incubated at 37°C in
a humidified atmosphere containing 5% CO2 until the
monolayer  was  formed. After  the  culture  medium
elimination,  two-fold  serial  dilution  of  the  samples
(100m l  of  each  dilution)  and  100m l  fresh  culture
medium  with  20m g/ml  of  actinomycin  D  (Serva,
Germany) were added, and further incubated for 18h
at  the  same  conditions.  Supernatants  were  then
removed  and  cells  stained  with  0.2%  crystal  violet
(Sigma,  USA). After  washing  and  drying  the  plates
were finally read at 540nm on a Titertek Multiskan
microElisa reader. Human recombinant TNF-a (Insti-
tute of Bioorganic Chemistry, Moscow, Russia) was
used as the internal standard. For the comparison of
an  experimental  and  calibrating  curves  the  probit-
analysis method was used. TNF content in the samples
was expressed in pg/ml.
IL-6 activity assay
IL-6 activity was determined using the IL-6-dependent
hybridoma cell line D6C8.15 Briefly, serial dilutions of
culture  supernatants  and  recombinant  IL-6  (code
89/45, NIBSC, UK) as a standard were incubated in
96-well microplates with cells (5 3 104 cells/well), in
a  total  volume  of  200m l  at  37°C. The  cells  were
cultivated  for  48h  in  RPMI-1640  medium  supple-
mented  with  5%  human  dialysed  AB-serum.  Four
hours  before  the  end of  cultivation  the  cells  were
pulsed  with  40kBq  per  well  of  [3H]-thymidine,
harvested with a cell harvester and counted by using
a liquid scintillation counter.
Statistical analysis
Statistical analysis was performed using the Student’s
t-test and chi-square statistic.
Results
Inhibition of lymphocyte proliferation
Inhibition of PHA-induced lymphocyte proliferation
in a dose-dependent manner by natural AGP (nAGP)
has  been  shown.  Both  lot  I  and  lot  II  markedly
suppressed cell proliferation but the inhibitory effect
of the latter was higher (Fig. 1). However, both curves
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conjugate,  so-called  pseudo-AGP ,  revealed  a  similar
antiproliferative effect. Also compared were AGP (lot
II)  with  pseudo-AGP  using  lymphocyte  stimulation
with  anti-CD3  antibodies.  Nearly  complete  coinci-
dence of the curves has been demonstrated (Fig. 2).
Table  1  summarizes  ED50 values  for  nAGP  and
pseudo-AGP . For chi-squared calculation ED50 values
for  pseudo-AGP  and  nAGP  were  considered  as
observed and expected numbers respectively. These
data show that no differences between pseudo-AGP
and nAGP (lot II) have been observed.
Stimulation of cytokine production
TNF-a and  IL-6  production  by  peripheral  blood
mononuclear cells, both were enhanced with nAGP
(Fig.  3).  Stimulation  of TNF-a production by nAGP
was observed within the dose range of 31–250m g/ml.
Pseudo-AGP showed the same stimulating properties.
In the same time, the maximum levels of the cytokine
production were higher than in the case of nAGP cell
treatment  and  the  curves  describing  nAGP  and
pseudo-AGP  stimulation  of  LPS-induced TNF-a pro-
duction were  somewhat  differ  in  profile  (Fig.  3A).
Stimulation of LPS-induced IL-6 production by nAGP
and pseudo-AGP was observed too. In this case the
curve profiles were similar (see Fig. 3B).
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FIG. 1. Inhibition of PHA-induced lymphocyte proliferation
with natural AGP (nAGP) and pseudo-AGP (see text). Periph-
eral blood mononuclear cells were stimulated with optimum
PHA dose and incubated for 72h in the presence of different
concentrations of nAGP or pseudo-AGP .
FIG. 2. Inhibition of anti-CD3 antibody-induced lymphocyte
proliferation with nAGP and pseudo-AGP . For the experiment
condition explanation see text and legend to Fig. 1.
FIG. 3. The effect of natural AGP (nAGP) and pseudo-AGP on
in  vitro TNF  (panel  A)  and  IL-6  (panel  B)  production  by
peripheral  blood  mononuclear  cells.  The  cells  were  incu-
bated  for  16–18h  with  LPS  in  the  presence  of  different
concentrations of nAGP or pseudo-AGP . The supernatants
were collected and TNF or IL-6 activity was quantified as
described in Materials and Methods. On the panel A Pvalues
are presented in comparison with a control.
Table 1. Comparison of antiproliferative effects of two AGP
lots with a neoglycoconjugate (NGC)
Inhibition of cell Lymphocyte ED50 values x 2 P
proliferation by stimulation (m g/ml)*
NGC PHA 246 ± 25
AGP (I) PHA 306 ± 62 19.27 < 0.05
AGP (II) PHA 233 ± 21 3.11 0.38
NGC CD3ab 281 ± 16
AGP (II) CD3ab 279 ± 15 0.058 0.996
*Date are mean ± SEM.Discussion
Pseudo-AGP  differs  from  natural  AGP  only  in  two
items:  (i)  it  has  no  protein  part,  (ii)  carbohydrate
chains are shuffled in it. As is shown above, pseudo-
AGP  completely  retains  the  ability  of  nAGP  to
modulate antiproliferative response of lymphocyte to
mitogens. Pseudo-AGP stimulates TNF and IL-6 pro-
duction  in  a  similar  manner,  its  effect  being  more
marked even than  nAGP action. It was also shown
earlier by flow cytometry analysis that pseudo-AGP
bound  selectively  with  blood  cells  similarly  to
nAGP .16
There  is  no  serious  contradictions  between  our
data and results published by Boutten et al.4 It is no
doubt that native AGP , asialo-AGP and AGP glycoforms
can potentiate the effect of LPS to the same degree,
especially when a single dose of the preparations have
been used. Earlier data showed that maximum immu-
nosuppressive effect  was obtained with asialo, aga-
lacto derivative of AGP . Further enzymatic removal of
mannose  and  N-acetyl  glucosamine  significantly
reduced  the  inhibitory  effects.11 Our  unpublished
data confirm these results. Moreover, the full deglyco-
sylation  resulted  in  peptide  core  denaturation  and
glycoprotein became insoluble. Because of that the
approach including quantitative translocation of car-
bohydrate chains from the protein onto protein free
polymer carrier has been performed.
Thus, it seems that carbohydrate chains of AGP play
a crucial role in the studied biological effect realiza-
tion. It is also demonstrated that the localization of
glycans on the carrier is not important for the effects
displayed. In prospect, on the basis of these results, it
is possible to create a family of artificial molecules
with  different  properties  by  the  various  glycan
translocation onto synthetic carrier.
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